1
|
Blight BJ, Gill AS, Sumsion JS, Pollard CE, Ashby S, Oakley GM, Alt JA, Pulsipher A. Cell Adhesion Molecules are Upregulated and May Drive Inflammation in Chronic Rhinosinusitis with Nasal Polyposis. J Asthma Allergy 2021; 14:585-593. [PMID: 34079296 PMCID: PMC8166329 DOI: 10.2147/jaa.s307197] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Accepted: 04/20/2021] [Indexed: 11/23/2022] Open
Abstract
Purpose Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly characterized by eosinophil- and T helper 2 cell (Th2)-biased inflammation. Integrins and intercellular adhesion molecules (ICAMs) are superfamilies of cell adhesion molecules (CAMs) that facilitate the recruitment and trafficking of immune cells and have been implicated in coordinating eosinophil and Th2 cell adhesion and signaling in asthma. The roles of CAMs in CRSwNP, however, remain poorly understood. The purpose of this study was to characterize the systemic and local expression of CAMs and identify which CAMs are potentially involved in CRSwNP pathology. Materials and Methods A prospective observational study was conducted using peripheral blood and anterior ethmoid tissues of patients with CRSwNP (n=32) and controls (n=15). Multiplex gene analysis and Pearson correlations were performed to identify associations between systemically and locally expressed CAMs. Based on the gene expression results, immunohistochemical evaluation and quantification of cells expressing integrins ITGAM, ITGAX, and ITGB2, as well as ICAM-3 in sinonasal tissues were conducted to compare local protein expression patterns. Results Integrin and ICAM genes were significantly elevated in the blood (p<0.001 to p<0.05) and sinuses (p<0.0003 to p<0.05) of patients with CRSwNP compared to controls. Strong positive correlations of genes expressed in the blood (p<0.01 to p<0.05) and sinuses (p<0.01) were observed between ITGAM, ITGAX, ITGB2, and ICAM3. ITGAM-, ITGB2-, ICAM-3-, and ICAM-3/ITGB2-positive cell counts were significantly increased in CRSwNP compared to controls (p<0.0001 to p<0.04), and a positive correlation between ICAM-3/ITGB2- and ITGAM-positive cell counts was observed (p<0.02). Conclusion The systemic and local expression of ITGAM, ITGB2, and ICAM-3 is significantly upregulated in CRSwNP, suggesting that integrin complex ITGAM/ITGB2 and ICAM-3 serve a potential role in inflammation-mediated signaling in CRSwNP.
Collapse
Affiliation(s)
- Brennan J Blight
- Division of Otolaryngology-Head and Neck Surgery, Rhinology-Sinus and Skull Base Surgery Program, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Amarbir S Gill
- Division of Otolaryngology-Head and Neck Surgery, Rhinology-Sinus and Skull Base Surgery Program, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Jorgen S Sumsion
- Division of Otolaryngology-Head and Neck Surgery, Rhinology-Sinus and Skull Base Surgery Program, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Chelsea E Pollard
- Division of Otolaryngology-Head and Neck Surgery, Rhinology-Sinus and Skull Base Surgery Program, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Shaelene Ashby
- Division of Otolaryngology-Head and Neck Surgery, Rhinology-Sinus and Skull Base Surgery Program, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Gretchen M Oakley
- Division of Otolaryngology-Head and Neck Surgery, Rhinology-Sinus and Skull Base Surgery Program, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Jeremiah A Alt
- Division of Otolaryngology-Head and Neck Surgery, Rhinology-Sinus and Skull Base Surgery Program, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Abigail Pulsipher
- Division of Otolaryngology-Head and Neck Surgery, Rhinology-Sinus and Skull Base Surgery Program, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
| |
Collapse
|
2
|
Zafra MP, Cañas JA, Mazzeo C, Gámez C, Sanz V, Fernández-Nieto M, Quirce S, Barranco P, Ruiz-Hornillos J, Sastre J, del Pozo V. SOCS3 silencing attenuates eosinophil functions in asthma patients. Int J Mol Sci 2015; 16:5434-51. [PMID: 25764157 PMCID: PMC4394485 DOI: 10.3390/ijms16035434] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Revised: 02/25/2015] [Accepted: 03/05/2015] [Indexed: 12/30/2022] Open
Abstract
Eosinophils are one of the key inflammatory cells in asthma. Eosinophils can exert a wide variety of actions through expression and secretion of multiple molecules. Previously, we have demonstrated that eosinophils purified from peripheral blood from asthma patients express high levels of suppressor of cytokine signaling 3 (SOCS3). In this article, SOCS3 gene silencing in eosinophils from asthmatics has been carried out to achieve a better understanding of the suppressor function in eosinophils. SOCS3 siRNA treatment drastically reduced SOCS3 expression in eosinophils, leading to an inhibition of the regulatory transcription factors GATA-3 and FoxP3, also interleukin (IL)-10; in turn, an increased STAT3 phosphorilation was observed. Moreover, SOCS3 abrogation in eosinophils produced impaired migration, adhesion and degranulation. Therefore, SOCS3 might be regarded as an important regulator implicated in eosinophil mobilization from the bone marrow to the lungs during the asthmatic process.
Collapse
Affiliation(s)
- Mª Paz Zafra
- Department of Immunology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain; E-Mails: (M.P.Z.); (J.A.C.); (C.M.); (C.G.); (V.S.)
- Centro de Investigación Biomedica En Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; E-Mails: (M.F.-N.); (S.Q.); (P.B.); (J.S.)
| | - Jose A. Cañas
- Department of Immunology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain; E-Mails: (M.P.Z.); (J.A.C.); (C.M.); (C.G.); (V.S.)
| | - Carla Mazzeo
- Department of Immunology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain; E-Mails: (M.P.Z.); (J.A.C.); (C.M.); (C.G.); (V.S.)
- Centro de Investigación Biomedica En Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; E-Mails: (M.F.-N.); (S.Q.); (P.B.); (J.S.)
| | - Cristina Gámez
- Department of Immunology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain; E-Mails: (M.P.Z.); (J.A.C.); (C.M.); (C.G.); (V.S.)
- Centro de Investigación Biomedica En Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; E-Mails: (M.F.-N.); (S.Q.); (P.B.); (J.S.)
| | - Veronica Sanz
- Department of Immunology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain; E-Mails: (M.P.Z.); (J.A.C.); (C.M.); (C.G.); (V.S.)
- Centro de Investigación Biomedica En Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; E-Mails: (M.F.-N.); (S.Q.); (P.B.); (J.S.)
| | - Mar Fernández-Nieto
- Centro de Investigación Biomedica En Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; E-Mails: (M.F.-N.); (S.Q.); (P.B.); (J.S.)
- Department of Allergy, Fundación Jiménez Díaz, 28040 Madrid, Spain
| | - Santiago Quirce
- Centro de Investigación Biomedica En Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; E-Mails: (M.F.-N.); (S.Q.); (P.B.); (J.S.)
- Department of Allergy, Hospital La Paz Health Research Institute (IdiPAZ), 28046 Madrid, Spain
| | - Pilar Barranco
- Centro de Investigación Biomedica En Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; E-Mails: (M.F.-N.); (S.Q.); (P.B.); (J.S.)
- Department of Allergy, Hospital La Paz Health Research Institute (IdiPAZ), 28046 Madrid, Spain
| | - Javier Ruiz-Hornillos
- Department of Allergy, Hospital Infanta Elena, Valdemoro, 28342 Madrid, Spain; E-Mail:
| | - Joaquín Sastre
- Centro de Investigación Biomedica En Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; E-Mails: (M.F.-N.); (S.Q.); (P.B.); (J.S.)
- Department of Allergy, Fundación Jiménez Díaz, 28040 Madrid, Spain
| | - Victoria del Pozo
- Department of Immunology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain; E-Mails: (M.P.Z.); (J.A.C.); (C.M.); (C.G.); (V.S.)
- Centro de Investigación Biomedica En Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; E-Mails: (M.F.-N.); (S.Q.); (P.B.); (J.S.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +34-915-504-891; Fax: +34-915-448-246
| |
Collapse
|
3
|
Mucosal Eosinophils. Mucosal Immunol 2015. [DOI: 10.1016/b978-0-12-415847-4.00044-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
4
|
Gupta A, Espinosa V, Galusha LE, Rahimian V, Miro KL, Rivera-Medina A, Kasinathan C, Capitle E, Aguila HA, Kachlany SC. Expression and targeting of lymphocyte function-associated antigen 1 (LFA-1) on white blood cells for treatment of allergic asthma. J Leukoc Biol 2014; 97:439-46. [PMID: 25341726 DOI: 10.1189/jlb.5hi0414-196r] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Allergic asthma is a chronic respiratory disease that results from an exaggerated inflammatory response in the airways. Environment stimuli, such as pollen and HDM, cause activation and migration of inflammatory WBCs into the respiratory tract, where they cause lung damage. Migration of these WBCs is dependent on the active configuration of the β2 integrin LFA-1. The experimental therapeutic agent LtxA specifically targets active LFA-1 and causes cell death. We investigated the association between LFA-1 and allergic asthma and hypothesized that targeting LFA-1 with LtxA could be an attractive strategy for treatment of the condition. We examined LFA-1 (CD11a) levels on PBMCs from patients with allergic asthma compared with healthy controls. Patients exhibited a significantly higher percentage of PBMCs expressing LFA-1 than healthy controls. Furthermore, the level of LFA-1 expression on patient PBMCs was greater than on healthy PBMCs. We identified a unique cellular population in patients that consisted of CD4(-) CD11a(hi) cells. We also evaluated LtxA in a HDM extract-induced mouse model for allergic asthma. LtxA caused resolution of disease in mice, as demonstrated by a decrease in BALF WBCs, a reduction in pulmonary inflammation and tissue remodeling, and a decrease in proinflammatory cytokines IL-4, IL-5, IL-9, IL-17F, and IL-23α in lung tissue. LFA-1 may serve as an important marker in allergic asthma, and the elimination of activated WBCs by use of LtxA could be a viable therapeutic strategy for treating patients with this condition.
Collapse
Affiliation(s)
- Anukriti Gupta
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| | - Vanessa Espinosa
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| | - Lindsey E Galusha
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| | - Vahid Rahimian
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| | - Katie L Miro
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| | - Amariliz Rivera-Medina
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| | - Chinnaswamy Kasinathan
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| | - Eugenio Capitle
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| | - Helen A Aguila
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| | - Scott C Kachlany
- *Department of Oral Biology, Rutgers School of Dental Medicine, Newark, New Jersey, USA; Departments of Medicine, Center for Immunity and Inflammation and Division of Allergy and Immunology, and Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey, USA; and Actinobac Biomed, New Brunswick, New Jersey, USA
| |
Collapse
|
5
|
Takayama G, Matsumoto K, Taira T, Aonuma M, Yokoyama M, Iigo Y, Takashi T. Improvement of pulmonary function by oral treatment with a VLA-4 antagonist in a mouse asthmatic model. J Pharmacol Sci 2014; 121:172-5. [PMID: 23419271 DOI: 10.1254/jphs.12198sc] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
We investigated in vivo efficacies of the newly synthesized VLA-4 antagonist Compound A {trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid} on Ascaris antigen-induced airway inflammation and hyperresponsiveness in a murine asthmatic model. Oral administration of Compound A significantly inhibited eosinophil infiltration into BALF and airway hyperresponsiveness 48 h after the antigen challenge. Histologic analysis of the lung sections confirmed the BALF result and revealed suppression of edema and mucus hyperplasia at 8 and 48 h after the challenge, respectively. These findings clearly show that orally active Compound A has therapeutic potential for treatment of asthma.
Collapse
|
6
|
Ghosh S, Hoselton SA, Dorsam GP, Schuh JM. Eosinophils in fungus-associated allergic pulmonary disease. Front Pharmacol 2013; 4:8. [PMID: 23378838 PMCID: PMC3561640 DOI: 10.3389/fphar.2013.00008] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Accepted: 01/10/2013] [Indexed: 12/30/2022] Open
Abstract
Asthma is frequently caused and/or exacerbated by sensitization to fungal allergens, which are ubiquitous in many indoor and outdoor environments. Severe asthma with fungal sensitization is characterized by airway hyperresponsiveness and bronchial constriction in response to an inhaled allergen that is worsened by environmental exposure to airborne fungi and which leads to a disease course that is often very difficult to treat with standard asthma therapies. As a result of complex interactions among inflammatory cells, structural cells, and the intercellular matrix of the allergic lung, patients with sensitization to fungal allergens may experience a greater degree of airway wall remodeling and progressive, accumulated pulmonary dysfunction as part of the disease sequela. From their development in the bone marrow to their recruitment to the lung via chemokine and cytokine networks, eosinophils form an important component of the inflammatory milieu that is associated with this syndrome. Eosinophils are recognized as complex multi-factorial leukocytes with diverse functions in the context of allergic fungal asthma. In this review, we will consider recent advances in our understanding of the molecular mechanisms that are associated with eosinophil development and migration to the allergic lung in response to fungal inhalation, along with the eosinophil’s function in the immune response to and the immunopathology attributed to fungus-associated allergic pulmonary disease.
Collapse
Affiliation(s)
- Sumit Ghosh
- Department of Veterinary and Microbiological Sciences, North Dakota State University Fargo, ND, USA
| | | | | | | |
Collapse
|
7
|
Saihkay HNS, Rickards KJ, Page CP, Ballinger JR. Validating 123I-metaiodobenzylguanidine as a platelet marker for non-invasive imaging in rabbits. J Pharmacol Toxicol Methods 2010; 63:69-78. [PMID: 20646985 DOI: 10.1016/j.vascn.2010.05.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2009] [Revised: 04/20/2010] [Accepted: 05/20/2010] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Recent in vitro studies in our laboratory have demonstrated that platelets are necessary for leukocyte recruitment and airway remodelling in models of allergic airway inflammation, and also migrate to lung tissues in response to anti-IgE or relevant allergens in allergic asthma. Non-invasive imaging of platelet migration in vivo would provide a further insight into the roles of platelets in inflammatory diseases such as asthma, and metaiodobenzylguanidine (MIBG) was considered as a suitable platelet marker. METHODS The kinetics of MIBG uptake into rabbit platelets, the effect of MIBG on platelet function and the effect of platelet activation on MIBG uptake and retention were investigated. MIBG-labelled platelets were administered intravenously into rabbits and the time course of radioactivity in the lung and blood was monitored as a function of stimulation. RESULTS Following a 4h incubation of MIBG in rabbit PRP, a near maximal MIBG uptake (52.4 ± 20.2%) in platelets occurred. This time point was chosen for subsequent in vitro studies. In vitro platelet function studies showed that MIBG has no effect on ADP or PAF-induced platelet aggregation, PAF-induced thromboxane production or fMLP-induced platelet chemotaxis. However, serotonin showed a significant effect on MIBG uptake and retention, but only at high concentrations. Stimulation of rabbit platelets with ADP and PAF caused a significant release of stored MIBG in vitro. Following i.v. administration of MIBG labelled platelets, the response to i.v. ADP and PAF stimulation was small but significant. DISCUSSION The release of MIBG from platelets in vivo, particularly following stimulation, leads to high background levels. Therefore, MIBG may have limited utility as a label for imaging platelets in vivo using PET. However, it may be a useful marker in detecting pathological conditions where platelet migration is involved.
Collapse
Affiliation(s)
- Hom N S Saihkay
- The Sackler Institute of Pulmonary Pharmacology, Waterloo Campus, King's College London, London SE1 9NH, UK.
| | | | | | | |
Collapse
|
8
|
Cell-permeable ceramides act as novel regulators of U937 cell–cell adhesion mediated by CD29, CD98, and CD147. Immunobiology 2010; 215:294-303. [DOI: 10.1016/j.imbio.2009.05.009] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2009] [Revised: 05/25/2009] [Accepted: 05/27/2009] [Indexed: 11/23/2022]
|
9
|
An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. Eur J Pharmacol 2008; 603:138-46. [PMID: 19103195 DOI: 10.1016/j.ejphar.2008.11.063] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2008] [Revised: 11/17/2008] [Accepted: 11/27/2008] [Indexed: 01/24/2023]
Abstract
Inhibition of the alpha4 subunit of both the alpha4beta1 and alpha4beta7 integrins has shown promise in decreasing airway inflammation and airway hyperresponsiveness in various animal models. We hypothesized that a novel, high-affinity alpha4beta1 antagonist (LLP2A) would decrease the migration of eosinophils to the lung and ameliorate the airway hyperresponsiveness in a mouse model of ovalbumin-induced airway inflammation. To test this hypothesis, we administered LLP2A, or scrambled LLP2A (a negative control), prior to exposure of sensitized BALB/c mice to ovalbumin aerosol. We can partially prevent, or reverse, the airway inflammatory response, but not airways hyperresponsiveness, by treatment of mice with LLP2A, a synthetic peptidomimetic alpha4beta1 antagonist. Specifically engineered, PEGylated (PEG) formulations of this antagonist further reduce the airway inflammatory response to ovalbumin, presumably by improving the circulating half-life of the drug.
Collapse
|
10
|
|
11
|
Schuster GU, Kenyon NJ, Stephensen CB. Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthma. THE JOURNAL OF IMMUNOLOGY 2008; 180:1834-42. [PMID: 18209081 DOI: 10.4049/jimmunol.180.3.1834] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The Th1/Th2 paradigm has become an important issue in the pathogenesis of asthma, characterized by normal Th1 and elevated Th2 cytokine expression. Vitamin A deficiency (VAD) can produce a Th1 bias, whereas high-level dietary vitamin A can promote a Th2 bias. We used the OVA exposure mouse model to determine the contributions of vitamin A-deficient, control (4IU/g), and high-level vitamin A (250-IU/g) diets to the development of allergic airway inflammation and hyperresponsiveness. VAD reduced serum IgE and IgG1 responses, pulmonary eosinophilia, and the levels of IL-4 and IL-5 in bronchoalveolar lavage specimens, whereas the 250-IU/g diet increased serum IgE. Also, VAD blocked pulmonary hyperresponsiveness following methacholine challenge while the 250-IU/g diet exacerbated pulmonary hyperresponsiveness. In conclusion, VAD diminished and high-level dietary vitamin A enhanced the development of experimental asthma in this model system. These data suggest that excessive intake of vitamin A may increase the risk or severity of asthma in industrialized countries whereas vitamin A deficiency continues to increase mortality from infectious diseases in developing countries.
Collapse
Affiliation(s)
- Gertrud U Schuster
- Nutrition Department, U.S. Department of Agriculture Western Human Nutrition Research Center, University of California-Davis, 430 West Health Science Drive, Davis, CA 95616, USA.
| | | | | |
Collapse
|
12
|
Cho JY. Chloroquine, an Anti-malarial Agent, Acts as a Novel Regulator of .BETA.1-Integrin-Mediated Cell-Cell Adhesion. Biol Pharm Bull 2008; 31:726-30. [DOI: 10.1248/bpb.31.726] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Jae Youl Cho
- School of Bioscience and Biotechnology, and Institute of Bioscience and Biotechnology, Kangwon National University
| |
Collapse
|
13
|
Barthel SR, Johansson MW, McNamee DM, Mosher DF. Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol 2007; 83:1-12. [PMID: 17906117 PMCID: PMC2859217 DOI: 10.1189/jlb.0607344] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Eosinophilic inflammation is a characteristic feature of asthma. Integrins are highly versatile cellular receptors that regulate extravasation of eosinophils from the postcapillary segment of the bronchial circulation to the airway wall and airspace. Such movement into the asthmatic lung is described as a sequential, multistep paradigm, whereby integrins on circulating eosinophils become activated, eosinophils tether in flow and roll on bronchial endothelial cells, integrins on rolling eosinophils become further activated as a result of exposure to cytokines, eosinophils arrest firmly to adhesive ligands on activated endothelium, and eosinophils transmigrate to the airway in response to chemoattractants. Eosinophils express seven integrin heterodimeric adhesion molecules: alpha 4 beta 1 (CD49d/29), alpha 6 beta 1 (CD49f/29), alpha M beta 2 (CD11b/18), alpha L beta 2 (CD11a/18), alpha X beta 2 (CD11c/18), alpha D beta2 (CD11d/18), and alpha 4 beta 7 (CD49d/beta 7). The role of these integrins in eosinophil recruitment has been elucidated by major advances in the understanding of integrin structure, integrin function, and modulators of integrins. Such findings have been facilitated by cellular experiments of eosinophils in vitro, studies of allergic asthma in humans and animal models in vivo, and crystal structures of integrins. Here, we elaborate on how integrins cooperate to mediate eosinophil movement to the asthmatic airway. Antagonists that target integrins represent potentially promising therapies in the treatment of asthma.
Collapse
Affiliation(s)
- Steven R. Barthel
- Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, WI 53706-1532
- Department of Medicine, University of Wisconsin-Madison, Madison, WI 53706-1532
| | - Mats W. Johansson
- Department of Medicine, University of Wisconsin-Madison, Madison, WI 53706-1532
| | - Dawn M. McNamee
- Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, WI 53706-1532
- Department of Medicine, University of Wisconsin-Madison, Madison, WI 53706-1532
| | - Deane F. Mosher
- Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, WI 53706-1532
- Department of Medicine, University of Wisconsin-Madison, Madison, WI 53706-1532
| |
Collapse
|
14
|
Ulyanova T, Priestley GV, Banerjee ER, Papayannopoulou T. Unique and redundant roles of alpha4 and beta2 integrins in kinetics of recruitment of lymphoid vs myeloid cell subsets to the inflamed peritoneum revealed by studies of genetically deficient mice. Exp Hematol 2007; 35:1256-65. [PMID: 17553614 PMCID: PMC2023970 DOI: 10.1016/j.exphem.2007.04.015] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2006] [Revised: 03/23/2007] [Accepted: 04/24/2007] [Indexed: 12/22/2022]
Abstract
OBJECTIVE Leukocyte recruitment to inflammatory sites is a prominent feature of acute and chronic inflammation. Instrumental in this process is the coordinated upregulation of leukocyte integrins (among which alpha4beta1 and beta2 integrins are major players) and their cognate receptors in inflamed tissues. To avoid the ambiguity of previous short-term antibody-based studies and to allow for long-term observation, we used genetically deficient mice to compare roles of alpha4 and beta2 integrins in leukocyte trafficking. MATERIALS AND METHODS Aseptic peritonitis was induced in alpha4 or beta2 integrin-deficient (conditional and conventional knockouts, respectively) and control mice, and recruitment of major leukocyte subsets to the inflamed peritoneum was followed for up to 4 days. RESULTS Despite normal chemokine levels in the peritoneum and adequate numbers, optimal recruitment of myeloid cells was impaired in both alpha4- and beta2-deficient mice. Furthermore, clearance of recruited neutrophils and macrophages was delayed in these mice. Lymphocyte migration to the peritoneum in the absence of alpha4 integrins was drastically decreased, both at steady state and during inflammation, a finding consistent with impaired lymphocyte in vitro adhesion and signaling. By contrast, in the absence of beta2 integrins, defects in lymphocyte recruitment were only evident when peritonitis was established. CONCLUSIONS Our data with concurrent use of genetic models of integrin deficiency reveal nonredundant functions of alpha4 integrins in lymphocyte migration to the peritoneum and further refine specific roles of alpha4 and beta2 integrins concerning trafficking and clearance of other leukocyte subsets at homeostasis and during inflammation.
Collapse
Affiliation(s)
- Tatiana Ulyanova
- Department of Medicine/Hematology University of Washington, Seattle, WA 98195, USA.
| | | | | | | |
Collapse
|
15
|
Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007; 119:1303-10; quiz 1311-2. [PMID: 17481712 DOI: 10.1016/j.jaci.2007.03.048] [Citation(s) in RCA: 292] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2007] [Revised: 03/27/2007] [Accepted: 03/28/2007] [Indexed: 02/08/2023]
Abstract
Blood eosinophilia and tissue eosinophilia are characteristic features of allergic inflammation and asthma, conditions associated with prominent production of T(H)2 cytokines IL-4, IL-5, and IL-13. In this review, we will consider recent advances in our understanding of the molecular mechanisms that promote expansion and differentiation of eosinophil progenitors in bone marrow, eosinophil recruitment in response to chemokine receptor 3 agonists eosinophil transit mediated by specific ligand-receptor interactions, and prolonged survival of eosinophils in peripheral tissues. Novel rational therapies including antiselectin and antichemokine receptor modalities designed to block eosinophil development and trafficking are discussed, together with the implications of recent clinical studies that have evaluated the efficacy of humanized anti-IL-5 mAb therapy.
Collapse
Affiliation(s)
- Helene F Rosenberg
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
| | | | | |
Collapse
|
16
|
Nadeem A, Obiefuna PCM, Wilson CN, Mustafa SJ. Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. Eur J Pharmacol 2006; 551:116-24. [PMID: 17027749 PMCID: PMC1766326 DOI: 10.1016/j.ejphar.2006.08.059] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2006] [Revised: 08/18/2006] [Accepted: 08/23/2006] [Indexed: 10/24/2022]
Abstract
Adenosine produces bronchoconstriction in allergic rabbits, primates, and humans by activating adenosine A(1) receptors. Previously, it is reported that a high dose of L-97-1, a water-soluble, small molecule adenosine A(1) receptor antagonist, blocks early and late allergic responses, and bronchial hyper-responsiveness to histamine in a hyper-responsive rabbit model of allergic asthma. Effects of a lower dose of L-97-1 are compared to montelukast, a cysteinyl leukotriene-1 receptor antagonist on early allergic response, late allergic response, bronchial hyper-responsiveness, and inflammatory cells in bronchoalveolar lavage (BAL) fluid following house dust mite administration. Rabbits received intraperitoneal injections of house dust mite extract within 24 h of birth followed by booster house dust mite injections. Hyper-responsive rabbits received aerosolized house dust mite (2500 allergen units), 1 h after intragastric administration of L-97-1 (1 mg/kg) or montelukast (0.15 mg/kg) and lung dynamic compliance was measured for 6 h. Lung dynamic compliance was significantly higher following L-97-1 at all time points and with montelukast at 60-300 min following house dust mite (P<0.05). L-97-1 blocks both early and late allergic responses. Montelukast blocks only the late allergic response. Both L-97-1 and montelukast significantly blocked bronchial hyper-responsiveness at 24 h (P<0.05). Both L-97-1 and montelukast significantly reduced BAL eosinophils at 6 h and neutrophils at 6 and 24 h (P<0.05). L-97-1 significantly reduced BAL lymphocytes at 6 and 24 h (P<0.05). Montelukast significantly reduced BAL macrophages at 6 and 24 h (P<0.05). By blocking both bronchoconstriction and airway inflammation, L-97-1 may be an effective oral anti-asthma treatment.
Collapse
Affiliation(s)
- Ahmed Nadeem
- Department of Pharmacology, East Carolina University, Greenville, NC, United States
| | | | | | | |
Collapse
|
17
|
Cortijo J, Sanz MJ, Iranzo A, Montesinos JL, Nabah YNA, Alfón J, Gómez LA, Merlos M, Morcillo EJ. A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. Br J Pharmacol 2006; 147:661-70. [PMID: 16432509 PMCID: PMC1751336 DOI: 10.1038/sj.bjp.0706658] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
alpha(4)beta(1) and alpha(4)beta(7) integrins are preferentially expressed on eosinophils and mononuclear leukocytes and play critical roles in their recruitment to inflammatory sites. We investigated the effects of TR14035, a small molecule, alpha(4)beta(1)/alpha(4)beta(7) dual antagonist, in a rat model of allergic asthma. Actively sensitized rats were challenged with aerosol antigen or saline on day 21, and the responses evaluated 24 and 48-h later. TR14035 (3 mg kg(-1), p.o.) was given 1-h before and 4-h after antigen or saline challenge. Airway hyper-responsiveness to intravenous 5-hydroxytryptamine was suppressed in TR14035-treated rats. Eosinophil, mononuclear cell and neutrophil counts, and eosinophil peroxidase and protein content in the bronchoalveolar lavage fluid (BALF) were decreased in TR14035-treated rats. Histological study showed a marked reduction of lung inflammatory lesions by TR14035. At 24-h postchallenge, antigen-induced lung interleukin (IL)-5 mRNA upregulation was suppressed in TR14035-treated rats. By contrast, IL-4 levels in BALF were not significantly affected by TR14035 treatment. IL-4 selectively upregulates vascular cell adhesion molecule-1 (VCAM-1), which is the main endothelial ligand of alpha(4) integrins. Intravital microscopy within the rat mesenteric microcirculation showed that 24-h exposure to 1 microg per rat of IL-4 induced a significant increase in leukocyte rolling flux, adhesion and emigration. These responses were decreased by 48, 100 and 99%, respectively in animals treated with TR14035. In conclusion, TR14035, by acting on alpha(4)beta(1) and alpha(4)beta(7) integrins, is an orally active inhibitor of airway leukocyte recruitment and hyper-responsiveness in animal models with potential interest for the treatment of asthma.
Collapse
Affiliation(s)
- Julio Cortijo
- Department of Pharmacology, Faculty of Medicine, University of Valencia, Avda. Blasco Ibañez, 15, 46010 Valencia, Spain
- Research Foundation, University General Hospital Consortium, Valencia, Spain
| | - María-Jesús Sanz
- Department of Pharmacology, Faculty of Medicine, University of Valencia, Avda. Blasco Ibañez, 15, 46010 Valencia, Spain
| | - Arantxa Iranzo
- Department of Pharmacology, Faculty of Medicine, University of Valencia, Avda. Blasco Ibañez, 15, 46010 Valencia, Spain
| | - José Luis Montesinos
- Department of Pharmacology, Faculty of Medicine, University of Valencia, Avda. Blasco Ibañez, 15, 46010 Valencia, Spain
| | - Yafa Naim Abu Nabah
- Department of Pharmacology, Faculty of Medicine, University of Valencia, Avda. Blasco Ibañez, 15, 46010 Valencia, Spain
| | - José Alfón
- Research Center, J. Uriach y Compañía S.A., Palau-solità i Plegamans, Barcelona, Spain
| | - Luis A Gómez
- Research Center, J. Uriach y Compañía S.A., Palau-solità i Plegamans, Barcelona, Spain
| | - Manuel Merlos
- Research Center, J. Uriach y Compañía S.A., Palau-solità i Plegamans, Barcelona, Spain
| | - Esteban J Morcillo
- Department of Pharmacology, Faculty of Medicine, University of Valencia, Avda. Blasco Ibañez, 15, 46010 Valencia, Spain
- Author for correspondence:
| |
Collapse
|
18
|
Ravensberg AJ, Luijk B, Westers P, Hiemstra PS, Sterk PJ, Lammers JW, Rabe KF. The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma. Allergy 2006; 61:1097-103. [PMID: 16918513 DOI: 10.1111/j.1398-9995.2006.01146.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Adhesion molecule very late antigen-4 (VLA-4) is implicated in the recruitment and activation of inflammatory cells in asthma, including eosinophils, T cells and mast cells. VLA-4 antagonists have been proposed as a new anti-inflammatory treatment modality for asthma. Therefore, we investigated whether a single inhaled dose of VLA-4 antagonist GW559090X could protect against allergen-induced changes in airway responses and airway inflammation in patients with asthma. We performed a randomized, double-blind, three-way crossover study with single inhaled doses of 3 mg of GW559090X, 500 microg of fluticasone propionate (FP) or placebo in 15 patients with mild intermittent asthma, controlled with short-acting beta(2)-agonists only. All patients developed a late asthmatic response (LAR) after allergen inhalation during screening. Study medication was administered 30 min prior to allergen challenge. Pre-dose and 24 h post-dose PC20 methacholine and levels of exhaled nitric oxide (eNO) were determined. At the given dose, VLA-4 antagonist GW559090X did not attenuate the early asthmatic response (EAR) when compared with placebo: mean AUC0-2 h(+/-SEM) (%fall h): 27.2+/-3.7 and 21.9+/-3.0 respectively (P=0.33); nor the LAR: mean AUC3-8 h(+/-SEM) (%fall h): 98.8+/-12.9 and 94.8+/-6.8 respectively (P=0.84). However, pretreatment with FP did attenuate both EAR and LAR when compared with placebo: mean AUC0-2 h11.6+/-3.3 (P=0.024) and mean AUC3-8 h 6.3+/-7.6 (P<0.001). None of these treatments had an effect on allergen-induced changes in airway hyper-responsiveness or eNO levels. These findings suggest that VLA-4 may not play a major role in allergen-induced airway responses and inflammation in asthma.
Collapse
Affiliation(s)
- A J Ravensberg
- Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
19
|
Küchler J, Grützkau A, Henz BM, Krüger-Krasagakis S. Morphological analysis of integrin-mediated adhesion of immature human mast cells to extracellular matrix proteins. Arch Dermatol Res 2006; 298:153-61. [PMID: 16865373 DOI: 10.1007/s00403-006-0676-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2005] [Revised: 05/19/2006] [Accepted: 06/13/2006] [Indexed: 11/30/2022]
Abstract
Specific heterodimers of alpha and beta integrins are implicated in mediating adhesion and functional activation of mast cells to extracellular matrix (ECM) proteins, determining thus homing, secretion and tissue distribution of these cells. In the present study, we have examined integrin expression and associated morphological features of mast cells adhering to ECM, also depending on cell activation and under the influence of protein kinase C (PKC) inhibitors. Unstimulated and PMA-activated human leukaemic mast cells (HMC-1 line) were allowed to adhere to fibronectin or vitronectin-coated surfaces. Cells were specifically stained for actin, beta(1, )alpha(1)-alpha(6), alpha(v) and alpha(v)beta(5 )integrins and were evaluated by fluorescence microscopy and confocal laser scan microscopy. Spontaneously adhering cells rapidly assumed an oblong shape, with pronounced formation of filopodia, whereas PMA-stimulated cells were round in shape. Clustering of integrins on filopodia and on comma-like shapes at the cell circumference in rounded cells was noted only for alpha(4), alpha(5) and beta(1 )chains in fibronectin-adhering cells, and for alpha(v) and alpha(v)beta(5) chains in vitronectin-adhering cells. On double staining, clustered integrins co-localized with each other and with actin at the cell membrane and along intracellular tension lines of actin filaments. PKC inhibitors affected the shape of cells, but adhesion was maintained. These data provide a morphological correlate to previously reported functional studies, demonstrating clustering of selected integrins during ECM adhesion at the cell membrane. This was associated with alignment of integrins along actin filaments within the cytoplasm, PKC signalling and changes in shape and activation of mast cells.
Collapse
Affiliation(s)
- Jens Küchler
- Department of Dermatology and Allergy, Charité, Humboldt University, Berlin, Germany
| | | | | | | |
Collapse
|
20
|
Brandt EB, Zimmermann N, Muntel EE, Yamada Y, Pope SM, Mishra A, Hogan SP, Rothenberg ME. The alpha4bbeta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine. Clin Exp Allergy 2006; 36:543-53. [PMID: 16630161 DOI: 10.1111/j.1365-2222.2006.02456.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Of the numerous adhesion molecules expressed by eosinophils, the alpha4-integrin has been identified as critically involved in eosinophil trafficking in the lung. Most studies have focused on the role of the alpha4beta1-adhesion complex, but eosinophils also express the alpha4beta7-integrin complex. OBJECTIVE To investigate the role of alpha4beta7, by assessing its membrane expression on eosinophils from different compartments using allergen-challenged mice and IL-4/IL-5 bi-transgenic mice. In addition, we aim to determine the impact of beta7-integrin deficiency on eosinophil recruitment to the lungs and intestine in specific experimental allergic models. RESULTS Evaluation of alpha4beta7 expression on bronchoalveolar lavage fluid (BALF) and lung tissue eosinophils revealed a down-regulation of this integrin as eosinophils migrate through the lungs. Indeed eosinophils isolated from the BALF and lung of allergic mice had low expression of the alpha4beta7-complex. While expression of the alpha4-chain remained unchanged, a significant decrease in beta7-surface expression was observed. Intestinal eosinophils, isolated from Peyer's patches, also displayed a down-regulation of the alpha4beta7-integrin, albeit only modest. In contrast, circulating eosinophils, isolated from the blood and spleen, expressed high levels of the alpha4beta7-integrin. However, eosinophil trafficking into the lungs of beta7-integrin-deficient mice was not significantly impaired in response to respiratory allergen challenges. In contrast, beta7-deficient mice had impaired eosinophil recruitment to the intestine. CONCLUSION Taken together, these results identify differential expression of the alpha4beta7-integrin on eosinophils and its critical role in regulating eosinophil responses in the intestine.
Collapse
Affiliation(s)
- E B Brandt
- Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Diamant Z, Kuperus J, Baan R, Nietzmann K, Millet S, Mendes P, Miller B, Amin D, Rohatagi S, Sterk PJ, Hoogsteden HC, Prins JB. Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin Exp Allergy 2006; 35:1080-7. [PMID: 16120091 DOI: 10.1111/j.1365-2222.2005.02296.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND Very late antigen-4 (VLA(4)) plays a key role in the recruitment of eosinophils in allergic responses in animal studies. OBJECTIVE We investigated whether pretreatment with multiple doses of a VLA(4) receptor antagonist, HMR 1031, protects against allergen-induced airway responses and airway inflammation in humans. METHODS Fourteen asthmatics (7F/7M), 18-49 years, PC(20) forced expiratory volume in 1 s (FEV(1)) methacholine (M) (<8 mg/mL; FEV(1) 82.3-116.1% predicted) with dual responses to inhaled allergen participated in a double-blind, placebo-controlled, cross-over study. Each treatment period consisted of 9 days, separated by >or=2 weeks. Exhaled nitric oxide (eNO), PC(20)FEV(1)(M) and hypertonic saline-induced sputum was obtained on Days 1, 7 and 9. Subjects inhaled HMR 1031 (20 mg b.i.d.) or placebo (P) on Days 1--8. On Day 8, an allergen bronchoprovocation test was performed, the airway response was measured by FEV(1), and expressed as %fall from baseline. Data from 12 evaluable subjects are presented here. RESULTS Both treatments were well tolerated. There was no significant difference between HMR 1031 and P in the early asthamatic response: mean AUC (0-3 h)+/-SEM (%fall h): 26.01+/-4.26 and 17.41+/-4.26, respectively (P=0.18), nor in the late response: mean AUC (3-9 h)+/-SEM (%fall h): 97.09+/-8.63 and 97.61+/-8.63, respectively, P=0.97. This corresponded to the absence of significant allergen-induced changes in PC(20)FEV(1)(M), eNO, sputum eosinophils and soluble inflammation markers between both treatment periods. CONCLUSIONS Treatment with multiple inhaled doses of the VLA(4) antagonist, HMR 1031, did not result in detectable protection against allergen-induced airway responses or airway inflammation in asthma.
Collapse
Affiliation(s)
- Z Diamant
- Erasmus University Medical Centre, Lung Function Lab, Rotterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Epstein MM. Targeting memory Th2 cells for the treatment of allergic asthma. Pharmacol Ther 2005; 109:107-36. [PMID: 16081161 DOI: 10.1016/j.pharmthera.2005.06.006] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2005] [Accepted: 06/21/2005] [Indexed: 12/19/2022]
Abstract
Th2 memory cells play an important role in the pathogenesis of allergic asthma. Evidence from patients and experimental models indicates that memory Th2 cells reside in the lungs during disease remission and, upon allergen exposure, become activated effectors involved in disease exacerbation. The inhibition of memory Th2 cells or their effector functions in allergic asthma influence disease progression, suggesting their importance as therapeutic targets. They are allergen specific and can potentially be suppressed or eliminated using this specificity. They have distinct activation, differentiation, cell surface phenotype, migration capacity, and effector functions that can be targeted singularly or in combination. Furthermore, memory Th2 cells residing in the lungs can be treated locally. Capitalizing on these unique attributes is important for drug development for allergic asthma. The aim of this review is to present an overview of therapeutic strategies targeting Th2 memory cells in allergic asthma, emphasizing Th2 generation, differentiation, activation, migration, effector function, and survival.
Collapse
Affiliation(s)
- Michelle M Epstein
- Medical University of Vienna, Department of Dermatology, Lazarettgasse 19, Vienna A-1090, Austria.
| |
Collapse
|
23
|
Obiefuna PCM, Batra VK, Nadeem A, Borron P, Wilson CN, Mustafa SJ. A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J Pharmacol Exp Ther 2005; 315:329-36. [PMID: 16020631 DOI: 10.1124/jpet.105.088179] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Adenosine, an important signaling molecule in asthma, produces bronchoconstriction in asthmatics. Adenosine produces bronchoconstriction in allergic rabbits, primates, and humans by activating A1 adenosine receptors (ARs). Effects of L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxyethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione] a water-soluble, small molecule A1 AR antagonist were investigated on early and late phase allergic responses (EAR and LAR) in a hyper-responsive rabbit model of asthma. Rabbits were made allergic by intraperitoneal injections of house dust mite [HDM; 312 allergen units (AU)] extract within 24 h of their birth. Booster HDM injections were given weekly for 1 month, biweekly for 4 months, and continued monthly thereafter. Hyperresponsiveness was monitored by measuring lung dynamic compliance (Cdyn), after histamine or adenosine aerosol challenge in allergic rabbits. Hyper-responsive rabbits were subjected to aerosol of HDM (2500 AU), 1 h after intragastric administration of L-97-1 (10 mg/kg) solution or an equivalent volume of saline. Cdyn was significantly higher after treatment with L-97-1 compared with untreated controls (p < 0.05 n = 5). Histamine PC30 was significantly higher (p < 0.05; n = 5) after L-97-1 at 24 h compared with histamine PC30 at 24 h after HDM. Adenosine PC30 was significantly higher at 15 min and 6 h after L-97-1 compared with control (p < 0.05; n = 5). L-97-1 showed strong affinity for human A1 ARs in radioligand binding studies and no inhibition toward human phosphodiesterase II, III, IV, and V enzymes. These data suggest that L-97-1 produces a significant reduction of histamine or adenosine-induced hyper-responsiveness and HDM-induced EAR and LAR in allergic rabbits by blocking A1 ARs and may be beneficial as an oral therapy for human asthma.
Collapse
Affiliation(s)
- P C M Obiefuna
- Department of Pharmacology, East Carolina University, Greenville, North Carolina, USA
| | | | | | | | | | | |
Collapse
|
24
|
Brakebusch C. Commentary 5. Exp Dermatol 2005. [DOI: 10.1111/j.0906-6705.2005.0323c.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Torres R, Picado C, de Mora F. [Use of the mouse to unravel allergic asthma: a review of the pathogenesis of allergic asthma in mouse models and its similarity to the condition in humans]. Arch Bronconeumol 2005; 41:141-52. [PMID: 15766467 DOI: 10.1016/s1579-2129(06)60415-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- R Torres
- Departamento de Farmacología, de Terapéutica y de Toxicología, Universidad Autónoma de Barcelona, Cerdanyola del Vallés, Barcelona, Spain
| | | | | |
Collapse
|
26
|
Burdon PCE, Martin C, Rankin SM. The CXC chemokine MIP-2 stimulates neutrophil mobilization from the rat bone marrow in a CD49d-dependent manner. Blood 2005; 105:2543-8. [PMID: 15542579 DOI: 10.1182/blood-2004-08-3193] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
AbstractThe acute release of neutrophils from the bone marrow is a critical step in their trafficking to sites of inflammation. This process is stimulated by systemically acting inflammatory mediators, such as the CXC chemokines. In this study we have used a novel in situ perfusion system of the rat femoral bone marrow to directly investigate the role of specific adhesion molecules in chemokine-stimulated neutrophil mobilization. We show here that neutrophils mobilized in response to rat macrophage inflammatory protein-2 (MIP-2) shed l-selectin and expressed significantly higher levels of CD11b and CD49d. However, inhibition of l-selectin sheddase activity with KD-IX-73-4 had no effect on the number of neutrophils mobilized in response to rat MIP-2. Blockade of CD18, using a neutralizing monoclonal antibody (mAb), did not inhibit neutrophil mobilization but unexpectedly increased the rate and number of neutrophils released from the bone marrow in response to chemokine, suggesting that CD18 could play a role in neutrophil retention within the bone marrow. Blockade of CD49d using either a selective mAb or a specific antagonist resulted in a dramatic inhibition (> 75%) of the chemokine-stimulated neutrophil mobilization from the bone marrow. These data reveal contrasting roles for CD18 and CD49d in the retention and release of neutrophils from the bone marrow.
Collapse
Affiliation(s)
- Peter C E Burdon
- Leukocyte Biology Section, Division of Biomedical Sciences, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Sir Alexander Fleming Bldg, Exhibition Rd, South Kensington, London SW7 2AZ, United Kingdom
| | | | | |
Collapse
|
27
|
Torres R, Picado C, de Mora F. Descubriendo el asma de origen alérgico a través del ratón. Un repaso a la patogenia de los modelos de asma alérgica en el ratón y su similitud con el asma alérgica humana. Arch Bronconeumol 2005. [DOI: 10.1016/s0300-2896(05)70605-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|